Clinical Trial

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Protocol Amendment History 79 amendments
This ClinicalTrials.gov record has been amended 79 times since 2017-09-29; most recent amendment 2026-05-01.
Status change: Recruiting → Active, Not Recruiting 2025-02-03
Status change: Active, Not Recruiting → Recruiting 2021-03-02
Status change: Suspended → Active, Not Recruiting 2020-10-05
Status change: Recruiting → Suspended 2019-12-09
Status change: Not Yet Recruiting → Recruiting 2017-11-29
Trial Details
NCT Number NCT03301506
Lead Sponsor Gilead Sciences
Conditions Primary Biliary Cirrhosis
Enrollment 340 participants
Start Date 2017-12-12
Primary Completion 2028-11 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-04